Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
The oral version delivers less weight loss than the injection (expected, given lower bioavailability), but still clinically meaningful especially for patients who would never self-inject
Both drugs carry the same FDA boxed warning (the most serious type of warning) about thyroid C-cell tumors found in rodent studies
All experiments were conducted with adherence to the National Institutes of Health Guide for the Care and Use of Laboratory Animals
OBES SURG 31(7):32793290 Al-Dohayan A, Qamhiah D, Abukhalaf A, Alomar A, Almutairi F, Alsalame N et al (2021) Cost effectiveness of bariatric surgery in patients with obesity related comorbidities: a retrospective study
On April 1, 2026, the FDA approved Eli Lillys FOUNDAYO (orforglipron) , the second oral GLP-1 approved for obesity, and arguably the one with the more patient-friendly convenience profile
